Item 8.01. Other Events.

On January 13, 2021, BeiGene, Ltd. ("BeiGene") announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer (NSCLC). This is the third approval in China for tislelizumab, and its first in a lung cancer indication. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.
   Exhibit No.           Description

       99.1              Press Release titled "China National Medical Products Administration
                         Approves Tislelizumab in Combination with Chemotherapy in First-Line
                         Advanced Squamous Non-Small Cell Lung Cancer" issued on January 13, 2021.

       104               The cover page from this Current Report on Form 8-K, formatted in Inline
                         XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses